75 results
8-K
EX-99
AEON
AEON Biopharma Inc. - Ordinary Shares
14 May 24
AEON Biopharma Reports First Quarter 2024 Financial Results
4:07pm
the development strategy for our pipeline.”
Recent Clinical and Corporate Highlights
Phase 2 study of ABP-450 in episodic and chronic migraine
DEFA14A
AEON
AEON Biopharma Inc. - Ordinary Shares
14 May 24
Additional proxy soliciting materials
9:14am
performed at four, eight and 12 weeks.
Our Strategy
Our goal is to change patients’ lives by enhancing the therapeutic botulinum toxin treatment paradigm … strategy will be driven by the following competitive strengths:
Well-Established 900 kDa Botulinum Toxin Complex. ABP-450 is the same botulinum toxin
8-K
EX-10.1
cykn2nghqkwfr4f8koha
19 Mar 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-10.6
4tlln20sk6x6kl
19 Mar 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-10.5
7wjm 7jxy
19 Mar 24
Entry into a Material Definitive Agreement
4:33pm
8-K
gk97ku33ej
19 Mar 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-10.2
xsydnfhm41nu3bez
19 Mar 24
Entry into a Material Definitive Agreement
4:33pm